NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond
| Website | http://www.novalgen.com |
| Employees | 11 (7 on RocketReach) |
| Founded | 2019 |
| Phone | +44 20 7139 8639 |
| Industry | Biotechnology, Pharmaceuticals |
| Keywords | Immuno-Oncology, Cancer Treatment, Immunotherapy, Oncology Drugs, Breakthrough Therapies, Targeted Therapy, Cancer Research, Pharmaceutical Research, Biotechnology, Clinical Trials, Drug Development, Novel Therapeutics, Immune System, Precision Medicine, Biopharma, Therapeutic Antibodies, Cancer Therapies, Pharmaceutical |
| Competitors | Roche, Merck & Co., Inc., AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Regeneron, Gilead Sciences, MedImmune, Lilly India +37 more (view full list) |
Looking for a particular NovalGen employee's phone or email?
NovalGen Questions
Amit Nathwani is the Founder and CEO of NovalGen.
7 people are employed at NovalGen.
Top NovalGen Employees
-
Amit Nathwani
Founder and CEO at NovalGen
London, GB2 -
David Granger
Vice President, R and D at NovalGen
Stevenage, GB2 -
41
-
Asha Dayalji
Account Assistant at NovalGen
United Kingdom2
Related Companies
G2Crowd Trusted
300K+
Plugin Users
